Table 2.

Multivariate Cox regression analysis of OS in 6-month follow-up cohort^a.

Covariate	Adjusted HR (95% CI)	P value
Treatment arm (venetoclax vs. placebo)	0.65 (0.46, 0.91)	0.012
Age group (<75 vs. ≥75 years)	0.59 (0.40, 0.86)	0.006
AML status (de novo vs. secondary)	0.61 (0.44, 0.86)	0.004
ECOG PS score (<2 vs. ≥2)	0.50 (0.35, 0.72)	<0.001
Cytogenetic risk (intermediate vs. poor)b	0.58 (0.41, 0.82)	0.002

^aBaseline characteristics included in the stepwise variable selection: treatment arm, age, sex, AML status, bone marrow blast count, ECOG PS score, cytogenetic risk group, prior HMA use, geographic region, FLT3 mutation status, IDH1/2 mutation status, and NMP1 mutation status. ^bFavorable vs. poor cytogenetic risk is not presented in this table as only comparisons with p-value ≤0.05 were included.

AML acute myeloid leukemia, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, FLT3 FMS-related tyrosine kinase 3, HMA hypomethylating agent, HR hazard ratio, IDH1/2 isocitrate dehydrogenase 1/2, NMP1 nucleophosmin, OS overall survival.